Gastrointestinal Infections

The US FDA has accepted a Biologics License Application (BLA) for Seres Therapeutics' SER-109, and set a Prescription Drug User Fee Act (PDUFA) action date of April 26, 2023.

A fecal microbiota transplant (FMT) trial was halted early due to clear evidence the treatment was superior to placebo.

The incubation period of the original, wild-type COVID-19 strain was 6.65 days, while the Omicron variant's incubation period has shortened to 3.42 days.

Frequent recurrence of Clostridioides difficile infection drives up financial burdens of the disease and underscores the need to improve access to treatment, infection prevention, and new therapies.

SER-109, the investigational oral microbiome therapeutic from Seres, reduced C diff recurrence by 91.3% in at-risk populations.

Seres Therapeutics shared phase 3 trial results demonstrating their investigational microbiome-based therapeutic, SER-109, prevented recurrent C difficile infection (rCDI) in 88% of recipients.

Today, the FDA approved vonoprazan dual and triple therapies, developed by Phathom Pharmaceuticals to treat adults with H. pylori infection.

In a small retrospective study, 7 of 11 patients experienced clinical improvement.

Rising sea temperatures cause Vibrio species, bacteria linked to gastroenteritis, to be identified for the first time in UK waters.

Underweight elderly pneumonia patients were more likely to contract C difficile infection.

For the first time, investigators proved that a higher presence of Clostridioides difficile bacteria and toxins cause a more severe infection.

A global study of C. difficile isolates worldwide found a very high prevalence of the bacteria on shoe soles.

Rare cases of health care–associated meningitis and ventriculitis in adults caused by Candida species are associated with recent bacterial meningitis and broad-spectrum antibiotic use.

Investigators apply guidelines into practical management strategies.

An assessment of the frontline agents show similarities infection cure and recurrence rates at 30 days.

A meta-analysis suggest the 2 first-line C diff therapies provide similar outcomes, yet differ in recurrent infection risk.

A study shows countries with the highest income levels had greater vaccine protection against rotavirus gastroenteritis (RVGE).

Experts discuss the bacteria’s transmission in the community setting, how to reduce disease and economic burdens, and ways to improve quality of life for patients.

Recommendations for treating C. difficile upon a first recurrence as well as following multiple recurrences based on currently available treatment options and recommendations by the IDSA/SHEA clinical practice guidelines.

A panel of clinicians recognize the challenges associated with screening patients for the C. difficile infection and highlight factors that should prompt someone for an evaluation.

Types of testing algorithms used in clinical practice to help clarify a diagnosis of C. difficile infection.

Important things to understand about diagnosing C. difficile and recommendations for properly differentiating the condition from other diseases when working-up a patient.

A discussion regarding the increasing frequency of C. difficile recurrence and its effects on patients and the healthcare system.

Sources of transmission and challenges that impact the management of community-onset C. difficile.

What healthcare providers need to know about the 2 strains of C. difficile, including types of patients impacted and typical outcomes.

Understanding the burden of C. difficile across the United States, panelists explore common risk factors associated with the condition and discuss the different ways it can manifest in patients.

Biologics have become a novel treatment in recurrent C. difficile.